HFS
INO icon

Hantz Financial Services’s Inovio Pharmaceuticals INO Stock Holding History

Hantz Financial Services’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
8
– – ﹤0.01% 2530
2025
Q4 		$0 Hold
8
– – ﹤0.01% 2474
2025
Q3 		$0 Hold
8
– – ﹤0.01% 2391
2025
Q2 		$0 Hold
8
– – ﹤0.01% 2238
2025
Q1 		$0 Hold
8
– – ﹤0.01% 1829
2024
Q4 		$0 Hold
8
– – ﹤0.01% 1149
2024
Q3 		$0 Hold
8
– – ﹤0.01% 1128
2024
Q2 		$0 Hold
8
– – ﹤0.01% 1162
2024
Q1 		$0 Sell
8
-1
-11% -$9 ﹤0.01% 1243
2023
Q4 		$0 Hold
9
– – ﹤0.01% 1171
2023
Q3 		$0 Hold
9
– – ﹤0.01% 1148
2023
Q2 		$0 Hold
9
– – ﹤0.01% 1127
2023
Q1 		$0 Hold
9
– – ﹤0.01% 1155
2022
Q4 		$0 Sell
9
-2
-18% -$45 ﹤0.01% 1118
2022
Q3 		$0 Buy
11
+2
+22% +$51 ﹤0.01% 1104
2022
Q2 		$0 Hold
9
– – ﹤0.01% 1075
2022
Q1 		$0 Buy
+9
New +$405 ﹤0.01% 1078
2021
Q4 		– Sell
-7
Closed -$1K – 885
2021
Q3 		$1K Sell
7
-325
-98% -$32.6K ﹤0.01% 792
2021
Q2 		$37K Buy
+332
New +$31.9K ﹤0.01% 574
2020
Q4 		– Sell
-267
Closed -$37K – 632
2020
Q3 		$37K Buy
+267
New +$55.7K ﹤0.01% 473

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hantz Financial Services's INO Position: Q1 2026 in Review

Hantz Financial Services held its Inovio Pharmaceuticals (INO) position steady in Q1 2026 at 8 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Hantz Financial Services first reported a position in INO in Q3 2020 and has held it in 20 quarters since. The position peaked at $37K in Q2 2021. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Hantz Financial Services held 8 shares of Inovio Pharmaceuticals worth $0 as of Q1 2026.
  • Hantz Financial Services left its Inovio Pharmaceuticals share count unchanged in Q1 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2530 holding.
  • Hantz Financial Services first reported a position in Inovio Pharmaceuticals in Q3 2020 and has held it in 20 quarters since.
  • Hantz Financial Services's Inovio Pharmaceuticals position peaked at $37K in Q2 2021.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.